| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | beta-amyloid (Aβ) |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| ECHA InfoCard | 100.133.214 |
| Chemical and physical data | |
| Formula | C6466H10018N1734O2026S44 |
| Molar mass | 145874.02 g·mol−1 |
  (what is this?) (verify) | |
Bapineuzumab (nicknamed "bapi")[1] is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma.[2] However, in 2012 it failed to produce significant cognitive improvements in patients in two major trials, despite lowering key biomarkers of AD, amyloid brain plaque and hyperphosphorylated tau protein in CSF.[3][4]
Bapineuzumab has been shown to recognise the extreme N-terminal 5 residues of Aβ peptide in a helical conformation (4HIX.pdb) stabilized by internal hydrogen bonds involving the first three amino acids.[5]
Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. In previous clinical trials for vaccination against human beta amyloid, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques, but 6% of subjects developed aseptic meningitis and the trial was stopped.[6]
- ^ Brandt C (Fall–Winter 2012). ""Team Babcock's" journey" (PDF). InSight. The Penn Memory Center (Penn Medicine): 1–3. Archived from the original (PDF) on 28 February 2014. Retrieved 1 Feb 2014.
- ^ Sample I (2007-08-07). "New Alzheimer's drugs might help prevent glaucoma". The Guardian. Retrieved 2008-06-18.
- ^ Berkrot B (7 August 2012). "Pfizer, J&J scrap Alzheimer's research as drug fails". Reuters.
- ^ "Alzheimer's disease drug shelved after trial failure". BBC News. 7 August 2012.
- ^ Miles LA, Crespi GA, Doughty L, Parker MW (2013-02-18). "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation". Scientific Reports. 3 (3): 1302. Bibcode:2013NatSR...3E1302M. doi:10.1038/srep01302. PMC 3575012. PMID 23416764.
- ^ Woodhouse A, Dickson TC, Vickers JC (2007). "Vaccination strategies for Alzheimer's disease: A new hope?". Drugs & Aging. 24 (2). Adis International: 107–19. doi:10.2165/00002512-200724020-00003. PMID 17313199. S2CID 28279428. Archived from the original on 2013-01-16. Retrieved 2010-07-27.
The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition.